Gordon, Louisa G.;
Leung, William;
Johns, Richard;
McNoe, Bronwen;
Lindsay, Daniel;
Merollini, Katharina M. D.;
Elliott, Thomas M.;
Neale, Rachel E.;
Olsen, Catherine M.;
Pandeya, Nirmala;
Whiteman, David C.
Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Estimated Healthcare Costs of Melanoma and Keratinocyte Skin Cancers in Australia and Aotearoa New Zealand in 2021
Beteiligte:
Gordon, Louisa G.;
Leung, William;
Johns, Richard;
McNoe, Bronwen;
Lindsay, Daniel;
Merollini, Katharina M. D.;
Elliott, Thomas M.;
Neale, Rachel E.;
Olsen, Catherine M.;
Pandeya, Nirmala;
Whiteman, David C.
Erschienen:
MDPI AG, 2022
Erschienen in:International Journal of Environmental Research and Public Health
Beschreibung:
<jats:p>Australia and Aotearoa New Zealand have the highest incidence of melanoma and KC in the world. We undertook a cost-of-illness analysis using Markov decision–analytic models separately for melanoma and keratinocyte skin cancer (KC) for each country. Using clinical pathways, the probabilities and unit costs of each health service and medicine for skin cancer management were applied. We estimated mean costs and 95% uncertainty intervals (95% UI) using Monte Carlo simulation. In Australia, the mean first-year costs of melanoma per patient ranged from AU$644 (95%UI: $642, $647) for melanoma in situ to AU$100,725 (95%UI: $84,288, $119,070) for unresectable stage III/IV disease. Australian-wide direct costs to the Government for newly diagnosed patients with melanoma were AU$397.9 m and AU$426.2 m for KCs, a total of AU$824.0 m. The mean costs per patient for melanoma ranged from NZ$1450 (95%UI: $1445, $1456) for melanoma in situ to NZ$77,828 (95%UI $62,525, $94,718) for unresectable stage III/IV disease. The estimated total cost to New Zealand in 2021 for new patients with melanoma was NZ$51.2 m, and for KCs, was NZ$129.4 m, with a total combined cost of NZ$180.5 m. These up-to-date national healthcare costs of melanoma and KC in Australia and New Zealand accentuate the savings potential of successful prevention strategies for skin cancer.</jats:p>